SPARE

A proSpective randomized controlled trial comParing infliximAb-antimetabolites combination therapy to anti-metabolites monotheRapy and infliximab monothErapy in Crohn’s disease patients in sustained steroid-free remission on combination therapy.

To demonstrate that Infliximab scheduled maintenance with or without antimetabolites is superior to antimetabolites alone to maintain sustained steroid-free remission over 2 years, while the latter is non inferior with regards to the mean time spent in remission over the same duration

 

 

Chief Investigator (UK): Prof. Jack Satsangi

Number and location of participating sites (by region/ country): 20 UK sites, also sites in France, Belgium, Sweden and Germany

EudraCT number: 2014-002311-41

 

Funder: European Commission 

Start and End date of grant award: 2015 - 2021

 

Current status: Closed: recruitment to the SPARE trial ended in March 2019 and the follow-up period has also now been completed

 

UK GDPR Privacy Statement: If you have participated in this study and would like to read how it complies with UK GDPR, please read this document.

 

UK Sponsor: University of Edinburgh & NHS Lothian ACCORD

CI: Prof Jack Satsangi

Trial Management Team: Julia Boyd

Research Nurse: Debbie Alexander

 

ECTU Involvement: Trial Management (UK only)

(UKCRC)

This article was published on